Spineart raised $31 million in capital increase to advance its spine product pipeline, according to a Sept. 26 news release.
The funding is backed by past investors, Gimv and EGS Beteiligungen. Spineart is known for its spine devices including the Baguera-C cervical disc replacement implant.
“Over the past years, we’ve made targeted strategic investments in product innovation, robotics, regulatory expansion in Europe and the United States and manufacturing, that are now coming to fruition,” Jerome Trividic, CEO of Spineart, said in the release. “With the continued support of Gimv and EGSB, we are well-positioned to scale globally, deliver innovative, differentiated technologies and reinforce our commitment to surgical excellence and improved patient outcomes.”
